Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    789.87
    +6.17 (+0.79%)
     
  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     
  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     
  • Bitcoin GBP

    48,490.43
    -1,578.08 (-3.15%)
     
  • CMC Crypto 200

    1,258.55
    -99.46 (-7.33%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • DOW

    39,512.84
    +125.08 (+0.32%)
     
  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     
  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

Hofseth Biocare ASA: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER IN HBC

James Berger, Chief Commercial Officer in Hofseth BioCare ASA, has today 01.10.2021 purchased 30,000 shares through his wholly-owned company Nevera AG, at an average price of NOK 6,65 per share.

Following this transaction, James Berger owns 3,297,955 shares corresponding to 0.92 % of the outstanding shares in Hofseth BioCare ASA and share options for a further 5,351,280 shares according to the stock exchange notice of 18.10.2019.

For further information, please contact:

Jon Olav Ødegård, CFO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act